Hengrui's First-in-Class Alzheimer's Injection SHR-3201 Approved for Clinical Trials

BEIJING — As the world races to crack one of medicine's most stubborn puzzles, Jiangsu Hengrui Pharmaceuticals Co., Ltd. is doubling down. China's largest drugmaker by market value said on Oct. 13 that a novel injection candidate targeting Alzheimer's disease has won regulatory approval to begin human trials — marking its second shot at a condition that has humbled the industry's biggest names.

The National Medical Products Administration (NMPA) greenlit clinical studies for SHR-3201 Injection, a candidate developed in-house by Hengrui's wholly owned subsidiary Beijing Shengdi Pharmaceutical Co., Ltd. As of the disclosure date, the company has poured roughly 48.8 million yuan (approximately $6.8 million) into the project, according to unaudited figures.

SHR-3201 is an innovative injectable formulation designed to clear disease-related biomarkers from patients' brains, with the goal of slowing the decline of cognitive function. According to the company, no drug with the same target and mechanism has been approved for market anywhere in the world, making it a first-in-class candidate.

The bet is a calculated one. Alzheimer's disease, a progressive neurodegenerative disorder with an insidious onset, is swelling in prevalence as China's population ages. The clinical gap remains enormous: globally, new-drug development for Alzheimer's is notoriously difficult, with high failure rates and few therapies that meaningfully slow cognitive decline. For a domestic innovator like Hengrui, the unmet need represents both a scientific imperative and a commercial opportunity.

SHR-3201 isn't Hengrui's first foray into Alzheimer's. Before this candidate cleared the clinical-trial threshold, the company had already advanced another candidate — SHR-1707 — into Phase II studies, making it one of the most progressed domestically developed anti-Alzheimer's monoclonal antibodies in China. SHR-1707 is a humanized anti-amyloid beta (Aβ) monoclonal antibody of the IgG1 subtype, also developed in-house.

Early data on SHR-1707 have been encouraging. At the 2023 Alzheimer's Association International Conference (AAIC), Hengrui presented two posters detailing results from a Phase I single-ascending-dose study conducted in healthy subjects in both China and Australia. The data showed that a single intravenous dose of 2 to 60 mg/kg was safe and well-tolerated in both younger and elderly subjects, with pharmacokinetic and pharmacodynamic profiles supportive of further clinical development. A Phase Ib multiple-ascending-dose study in Chinese Alzheimer's patients was also underway, the company disclosed.

The approval of SHR-3201 enriches Hengrui's pipeline in neurodegenerative diseases, a strategic priority as the company broadens its innovation matrix beyond oncology and metabolic disorders into the central nervous system. The push into high-barrier therapeutic areas reflects a deliberate strategy to differentiate in an increasingly crowded pharmaceutical market.

The financials underscore the company's commitment. In the first half of 2026, Hengrui's innovative-drug sales reached 8.809 billion yuan (approximately $1.23 billion), up 16.38% year over year. For the first time, innovative drugs accounted for more than 60% of total pharmaceutical revenue, hitting 63.16% of the company's drug sales. Behind that shift is serious R&D spending: the company invested 4.605 billion yuan (approximately $643 million) in research and development during the period, a 18.96% year-over-year increase that represented 29.8% of total revenue.

Still, the road ahead is far from certain. Alzheimer's drug development demands years of multi-phase clinical trials, each requiring rigorous validation of efficacy and safety. Regulatory approval is far from guaranteed, and whether any candidate — including SHR-3201 — will ultimately reach commercialization remains an open question. For Hengrui, the wager is that disciplined innovation in high-unmet-need areas will set it apart in a market where me-too drugs are losing their edge.